Best Practice & Research Clinical Haematology

Papers
(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia36
How do molecular aberrations guide therapy in MDS?25
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders19
Myeloproliferative neoplasms in adolescents and young adults18
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?17
Preface of special edition “Biostatistics in clinical haematology”17
Donor lymphocyte infusion in Acute Myeloid Leukemia16
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents14
HLA structure and function in hematopoietic-cell transplantation14
From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation14
Editorial Board13
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration12
Considerations to comprehensive care for the older individual with myelofibrosis12
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry12
Cytomegalovirus in haematopoietic cell transplantation - The troll is still there12
Contemporary and future strategies in polycythemia vera12
Marrow failure and aging: The role of “Inflammaging”11
Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors11
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma11
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults10
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?10
Addressing symptom burden in myeloproliferative neoplasms10
Changing trends in the therapy of acute myeloid leukemia10
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma10
Treatment of telomeropathies10
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation8
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-197
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis7
The role of registries in hematological disorders7
The role of randomized controlled trials, registries, observational databases in evaluating new interventions7
Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry6
Clinical experience of CAR T cells for multiple myeloma6
Corrigendum to “HIV-associated lymphoma” [Best Pract Res Clin Haematol 25 (2012) 101–117]6
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia5
COVID-19 and antiphospholipid antibodies5
Editorial Board / Aims & Scope5
Bone marrow failure syndromes5
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage5
Novel therapeutic targets for chronic myelomonocytic leukemia5
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances5
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes5
Editorial Board / Aims & Scope5
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)5
Cardio-oncology and transplantation for acute myeloid leukemia5
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy5
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment5
How can we design a better care model to address the acute distress of an acute leukemia diagnosis? Care models to address the acute distress of an acute leukemia diagnosis5
0.052474021911621